Surmodics (SRDX) Competitors $36.00 +3.95 (+12.32%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$38.12 +2.13 (+5.90%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRDX vs. ATEC, ATRC, IART, OFIX, ANGO, ARAY, RMTI, RSLS, ABT, and ISRGShould you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include Alphatec (ATEC), AtriCure (ATRC), Integra LifeSciences (IART), ORTHOFIX MEDICAL (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), and Intuitive Surgical (ISRG). These companies are all part of the "health care equipment" industry. Surmodics vs. Its Competitors Alphatec AtriCure Integra LifeSciences ORTHOFIX MEDICAL AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Intuitive Surgical Alphatec (NASDAQ:ATEC) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Which has preferable earnings and valuation, ATEC or SRDX? Surmodics has lower revenue, but higher earnings than Alphatec. Surmodics is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlphatec$611.56M2.59-$162.12M-$1.15-9.41Surmodics$121.58M4.23-$11.54M-$1.39-25.90 Do analysts recommend ATEC or SRDX? Alphatec currently has a consensus target price of $18.13, suggesting a potential upside of 67.51%. Surmodics has a consensus target price of $43.00, suggesting a potential upside of 19.44%. Given Alphatec's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alphatec is more favorable than Surmodics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alphatec 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Surmodics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to ATEC or SRDX? In the previous week, Alphatec had 2 more articles in the media than Surmodics. MarketBeat recorded 6 mentions for Alphatec and 4 mentions for Surmodics. Surmodics' average media sentiment score of 0.71 beat Alphatec's score of 0.44 indicating that Surmodics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphatec 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Surmodics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ATEC or SRDX more profitable? Surmodics has a net margin of -16.34% compared to Alphatec's net margin of -25.77%. Surmodics' return on equity of -7.10% beat Alphatec's return on equity.Company Net Margins Return on Equity Return on Assets Alphatec-25.77% -1,657.19% -21.53% Surmodics -16.34%-7.10%-4.77% Do insiders and institutionals hold more shares of ATEC or SRDX? 66.4% of Alphatec shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 20.9% of Alphatec shares are held by insiders. Comparatively, 8.9% of Surmodics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, ATEC or SRDX? Alphatec has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. SummaryAlphatec and Surmodics tied by winning 8 of the 16 factors compared between the two stocks. Get Surmodics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRDX vs. The Competition Export to ExcelMetricSurmodicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$458.28M$10.55B$5.70B$9.50BDividend YieldN/A2.00%4.60%4.01%P/E Ratio-25.9017.0728.1020.05Price / Sales4.2329.18429.3789.38Price / Cash103.5923.0336.2258.56Price / Book4.323.698.665.87Net Income-$11.54M$234.77M$3.25B$258.55M7 Day Performance19.17%6.32%4.22%3.73%1 Month Performance23.75%7.94%10.51%11.75%1 Year Performance-13.13%-13.57%34.40%18.03% Surmodics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRDXSurmodics4.0254 of 5 stars$36.00+12.3%$43.00+19.4%-13.4%$458.28M$121.58M-25.90450News CoverageUpcoming EarningsHigh Trading VolumeATECAlphatec3.9107 of 5 stars$10.31-1.7%$18.13+75.8%-0.5%$1.53B$611.56M-8.97700News CoveragePositive NewsUpcoming EarningsATRCAtriCure3.3316 of 5 stars$29.24-0.1%$50.67+73.3%+33.9%$1.45B$465.31M-36.101,300News CoveragePositive NewsUpcoming EarningsIARTIntegra LifeSciences4.1407 of 5 stars$11.37+2.2%$18.63+63.8%-58.4%$864.94M$1.61B4.604,396News CoverageUpcoming EarningsOFIXORTHOFIX MEDICAL2.7408 of 5 stars$10.67+0.4%$21.50+101.5%-31.7%$416.49M$799.49M0.001,616ANGOAngioDynamics3.9515 of 5 stars$8.99+3.5%$19.00+111.3%+22.8%$352.88M$292.50M-10.83760ARAYAccuray3.1256 of 5 stars$1.34+0.4%N/A-27.3%$137.52M$446.55M0.001,040News CoveragePositive NewsRMTIRockwell Medical3.9965 of 5 stars$1.12+1.8%$4.00+257.1%-42.2%$37.59M$101.49M0.00300Positive NewsRSLSReShape Lifesciences0.4256 of 5 stars$2.91-8.5%N/A-99.2%$7.59M$8.01M0.0050Positive NewsABTAbbott Laboratories4.9902 of 5 stars$124.27+0.5%$144.47+16.3%+19.4%$215.17B$41.95B15.57114,000ISRGIntuitive Surgical4.7034 of 5 stars$516.12-0.5%$592.86+14.9%+13.5%$185.88B$8.35B81.4215,638Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies Alphatec Competitors AtriCure Competitors Integra LifeSciences Competitors ORTHOFIX MEDICAL Competitors AngioDynamics Competitors Accuray Competitors Rockwell Medical Competitors ReShape Lifesciences Competitors Abbott Laboratories Competitors Intuitive Surgical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRDX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
